CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This is a non-profit phase II, randomized clinical study of the combination of avelumab plus
cetuximab as rechallenge strategy, compared to cetuximab alone, in pre-treated RAS/BRAF wild
type metastatic colorectal cancer patients (according to liquid biopsy at baseline). Patients
have been treated in first line with chemotherapy in combination with cetuximab and have had
a clinical benefit (complete or partial response) from treatment.